Skip to main content

Zegerid OTC Side Effects

Generic name: omeprazole / sodium bicarbonate

Medically reviewed by Last updated on Jan 11, 2024.

Note: This document contains side effect information about omeprazole / sodium bicarbonate. Some dosage forms listed on this page may not apply to the brand name Zegerid OTC.

Applies to omeprazole / sodium bicarbonate: oral capsule, oral packet, oral powder for suspension.

Serious side effects of Zegerid OTC

Along with its needed effects, omeprazole/sodium bicarbonate may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking omeprazole / sodium bicarbonate:

More common

Less common


Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking omeprazole / sodium bicarbonate:

Symptoms of overdose

Other side effects of Zegerid OTC

Some side effects of omeprazole / sodium bicarbonate may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Incidence not known

For Healthcare Professionals

Applies to omeprazole / sodium bicarbonate: oral capsule, oral powder for reconstitution, oral suspension.


Very common (10% or more): Pyrexia (Up to 20.2%)

Common (1% to 10%): Hyperpyrexia


Common (1% to 10%): Asthenia

Postmarketing reports: Fatigue, fever, malaise, pain, tinnitus[Ref]


Very common (10% or more): Hypokalemia (Up to 12.4%), hyperglycemia NOS (Up to 10.7%), hypomagnesemia (Up to 10.1%)

Common (1% to 10%): Fluid overload, hyperkalemia, hypernatremia, hypocalcemia, hypoglycemia NOS, hyponatremia, hypophosphatemia

Frequency not reported: Cyanocobalamin (vitamin B-12) deficiency


Postmarketing reports: Anorexia, hypoglycemia, hypomagnesemia, hyponatremia, weight gain

Sodium Bicarbonate:

Postmarketing reports: Metabolic acidosis, tetany[Ref]


Very common (10% or more): Nosocomial pneumonia (Up to 11.2%)

Common (1% to 10%): Acute respiratory distress syndrome, respiratory failure

Uncommon (0.1% to 1%): Pneumothorax NOS


Common (1% to 10%): Cough, upper respiratory infection

Postmarketing reports: Bronchospasm, epistaxis, pharyngeal pain[Ref]


Very common (10% or more): Thrombocytopenia (Up to 10.1%)

Common (1% to 10%): Anemia NOS, anemia NOS aggravated


Postmarketing reports: Agranulocytosis/fatal agranulocytosis, anemia, hemolytic anemia, leukocytosis, leukopenia, neutropenia, pancytopenia, thrombocytopenia[Ref]


Common (1% to 10%): Atrial fibrillation, bradycardia not otherwise specified (NOS), edema NOS, hypertension NOS, hypotension NOS, supraventricular tachycardia, tachycardia NOS, ventricular tachycardia


Postmarketing reports: Bradycardia, chest pain/angina, elevated blood pressure, palpitation, peripheral edema, tachycardia[Ref]


Common (1% to 10%): Constipation, diarrhea NOS, gastric hypomobility, oral candidiasis

Frequency not reported: Clostridium difficile-associated diarrhea, fundic gland polyps, upper gastrointestinal bleeding


Common (1% to 10%): Abdominal pain, acid regurgitation, constipation, diarrhea, flatulence, nausea, vomiting

Postmarketing reports: Abdominal swelling, Clostridium difficile associated diarrhea, dry mouth, esophageal candidiasis, fecal discoloration, gastric fundic gland polyps, irritable colon, mucosal atrophy of the tongue, pancreatitis/fatal pancreatitis, stomatitis[Ref]

Benign gastric fundic gland polyps occurred rarely and appeared to be reversible when omeprazole was discontinued.[Ref]


Common (1% to 10%): Decubitus ulcer, rash NOS

Frequency not reported: Cutaneous lupus erythematosus, systemic lupus erythematosus


Common (1% to 10%): Rash

Postmarketing reports: Alopecia, cutaneous lupus erythematosus, dry skin, erythema multiforme/severe erythema multiforme, hyperhidrosis, photosensitivity, pruritus, purpura and/or petechia with/without rechallenge, severe generalized skin reactions, skin inflammation, Stevens-Johnson syndrome, systemic lupus erythematosus, toxic epidermal necrolysis (TEN)/fatal TEN, urticaria[Ref]


Common (1% to 10%): Abnormal liver function tests NOS


Postmarketing reports: Hepatocellular/cholestatic/mixed hepatitis, jaundice, liver failure/fatal liver failure, liver necrosis/fatal liver necrosis, mild to marked elevation of liver function tests (alkaline phosphatase, ALT, AST, gamma-glutamyl transpeptidase), overt liver disease[Ref]


Common (1% to 10%): Candidal infection NOS, sepsis NOS[Ref]


Common (1% to 10%): Agitation


Postmarketing reports: Abnormal dreams, aggression, agitation, anxiety, apathy, confusion, depression, hallucinations, insomnia, nervousness, psychiatric disturbances[Ref]


Common (1% to 10%): Urinary tract infection, urinary tract infection NOS


Postmarketing reports: Hematuria, microscopic pyuria, proteinuria, testicular pain, urinary frequency, urinary tract infection[Ref]

Nervous system


Common (1% to 10%): Headache, dizziness

Postmarketing reports: Hemifacial dysesthesia, hepatic encephalopathy, paresthesia, somnolence, taste perversion, tremors, vertigo

Sodium Bicarbonate:

Postmarketing reports: Seizures[Ref]


Frequency not reported: Bone fracture


Common (1% to 10%): Back pain

Postmarketing reports: Bone fracture, joint pain, leg pain, muscle cramps, muscle weakness, myalgia[Ref]



Postmarketing reports: Anterior ischemic optic neuropathy, blurred vision, double vision, dry eye syndrome, ocular irritation, optic atrophy, optic neuritis[Ref]



Postmarketing reports: Anaphylactic shock, anaphylaxis, angioedema, hypersensitivity reactions[Ref]


Frequency not reported: Acute interstitial nephritis


Postmarketing reports: Elevated serum creatinine, glycosuria, interstitial nephritis with/without positive rechallenge[Ref]



Postmarketing reports: Gastroduodenal carcinoids[Ref]

Gastroduodenal carcinoids have been reported in patients with Zollinger-Ellison syndrome on long-term therapy. This condition may be a manifestation of the underlying condition, which is known to be associated with these tumors.[Ref]



Postmarketing reports: Gynecomastia[Ref]

More about Zegerid OTC (omeprazole / sodium bicarbonate)

Patient resources

Other brands


Professional resources

Other brands


Other formulations

Related treatment guides


1. Product Information. Zegerid (omeprazole). Santarus Inc. 2004.

2. Product Information. Zegerid (omeprazole-sodium bicarbonate). Santarus Inc. 2006.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.